Moody Aldrich Partners’s Edgewise Therapeutics EWTX Stock Holding History

Moody Aldrich Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.26M	Sell	104,952 -9,189	-8%	-$317K	0.77%	60
2026 Q1	$3.6M	Buy	114,141 +71,007	+165%	+$2.05M	0.65%	75
2025 Q4	$1.07M	Sell	43,134 -39,807	-48%	-$799K	0.2%	117
2025 Q3	$1.35M	Sell	82,941 -16,907	-17%	-$240K	0.26%	110
2025 Q2	$1.31M	Sell	99,848 -82,247	-45%	-$1.19M	0.25%	107
2025 Q1	$4.01M	Sell	182,095 -5,837	-3%	-$153K	0.84%	53
2024 Q4	$5.02M	Buy	187,932 +36,775	+24%	+$1.17M	0.93%	37
2024 Q3	$4.03M	Buy	+151,157	New	+$3.01M	0.73%	63

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Moody Aldrich Partners's EWTX Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Edgewise Therapeutics (EWTX) stake by 8.1% in Q2 2026, selling an estimated $317K and leaving 104,952 shares worth $4.26M. The position accounts for 0.77% of the portfolio, ranked #60.

Moody Aldrich Partners first reported a position in EWTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.02M in Q4 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Moody Aldrich Partners held 104,952 shares of Edgewise Therapeutics worth $4.26M as of Q2 2026.
Moody Aldrich Partners sold 9,189 Edgewise Therapeutics shares in Q2 2026, an estimated $317K.
Edgewise Therapeutics made up 0.77% of Moody Aldrich Partners's portfolio in Q2 2026, its #60 holding.
Moody Aldrich Partners first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 8 quarters since.
Moody Aldrich Partners's Edgewise Therapeutics position peaked at $5.02M in Q4 2024.
223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.